Episode Details

WW (WW International) reported Q1 FY2026 earnings on 2026-05-07. Stock jumped 1.3% on the print. Here's the breakdown: Is WW a buy, hold, or sell after this quarter? In this WW International (WW) Q1 FY2026 earnings breakdown we cover the revenue and EPS print, the 8-quarter trend, segment detail, the free-cash-flow bridge, forward guidance, peer valuation, and management & earnings quality - ending with a clear price-aware Buy / Hold / Avoid Call and a Wall Street consensus comparison. If you follow Consumer stocks or WW earnings, this is the Q1 FY2026 deep dive. 🎧 Listen on Podbean: https://chargedalpha.podbean.com (also on Apple Podcasts & Spotify) 🔔 Subscribe for daily earnings deep-dives → @ChargedAlpha | Call tracker: chargedalpha.com THE CALL: AVOID (4/5 conviction, STRONG) - CURRENT @ $18.80 - AVOID - BUY below $10.00 with $8.00 stop - AVOID above $24.00 TRIGGER: Two consecutive quarters of stabilizing subscriber counts plus positive operating cash flow would change the conversation; absent that, the thesis stays AVOID WINDOW: Reassess each quarterly print - a strategic-review outcome could compress timing either way TRACKER: chargedalpha.com WALL STREET CONSENSUS - Ratings: 0 Strong Buy / 0 Buy / 2 Hold / 1 Sell / 0 Strong Sell - HOLD - Median 12-month price target: $27.25 (range $20 - $35) - Charged Alpha vs consensus: MORE BEARISH THESIS WW is the casualty side of the GLP-1 disruption trade. The Chapter 11 process cleaned the debt but did not solve a demand problem that is structural, not cyclical. Bull lever: A clean balance sheet, a recognized brand, and a small but fast-growing clinical telehealth segment offer optionality if the company can stabilize subscribers and find a strategic partner. Key risk: Subscriber attrition at minus 22% and revenue at minus 9.8% with a 40 million dollar quarterly free-cash-flow burn against 127 million dollars in cash means the runway is short - under a year - without a financing event or sale. QUALITY CHECK - Management quality grade: C (CEO Tara Comonte stepped in during the bankruptcy process and inherited a structurally challenged business.) - Earnings quality grade: D (The Q1 print contains no cosmetic adjustments - the loss is real.) CHAPTERS 0:00 Hook 0:13 The Year in One Chart 0:53 The Print 1:36 Beat Decomposition 2:16 The Trend 3:00 The Segments 3:45 The FCF Bridge 4:28 Margin Quality 5:16 Guidance & The Narrative Diff 6:16 Catalyst Calendar 6:54 Peer Dot-Plot 7:38 Valuation 8:18 Management & Earnings Quality 9:06 The Call - Verdict 9:49 The Call - Evidence 10:33 The Call - Supporting Figures KEY METRICS - Q1 FY2026 - Revenue: $0.17B (YoY -9.8%, beat est by -3.8%) - EPS: $-5.20 (vs $-2.44 est) - Operating margin: -17.6% - Free cash flow: $-0.04B (-23.4% margin) NARRATIVE DIFF - what changed in management tone - Prior call: "On the post-emergence Q3 2025 call, prior management framed the restructure as the start of a turnaround anchored by GLP-1-compatible clinical services." - This call: "We are not yet at an inflection point and our strategic review is ongoing." - Tone shift: The miss was wider than expected on every line. The Chapter 11 restructure cleaned the balance sheet but did not solve the demand problem. GLP-1 weight-loss drugs are not a one-time shock - they are a permanent change in the addressable market. DATA SOURCES - FMP (financialmodelingprep.com) - WW International Q1 FY2026 press release + earnings call DISCLAIMER This is for informational and educational purposes only. Not financial advice. Charged Alpha does not have a position in WW. Do your own research before any investment decision. - WW stock analysis | WW International Q1 FY2026 earnings | is WW a buy, hold or sell | WW stock forecast | WW price target | Consumer stocks to watch | Consumer earnings | stock market news | earnings season 2026 | how to invest in WW | WW International stock analysis | dividend & growth stock research | Charged Alpha